Isofol Medical AB (publ) (STO:ISOFOL)
0.9900
+0.0350 (3.66%)
Nov 20, 2026, 5:29 PM CET
Isofol Medical AB Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
7
Market Cap
317.29M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 721.00K | -12.08M | -94.37% |
| Dec 31, 2022 | 12.80M | -9.61M | -42.89% |
| Dec 31, 2021 | 22.41M | -14.73M | -39.66% |
| Dec 31, 2020 | 37.14M | 37.03M | 34,607.48% |
| Dec 31, 2019 | 107.00K | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | 227.00K | -281.00K | -55.31% |
| Dec 31, 2016 | 508.00K | 321.00K | 171.66% |
| Dec 31, 2015 | 187.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Cantargia AB | 317.31M |
| Sprint Bioscience AB | 134.13M |
| Xbrane Biopharma AB | 127.95M |
| Intervacc AB | 18.44M |
| Corline Biomedical AB | 12.63M |
| Elicera Therapeutics AB | 7.79M |
| Xspray Pharma AB | 7.19M |
| Simris Group AB (PUBL) | 1.14M |
Isofol Medical AB News
- 10 days ago - Isofol Medical AB Quarterly report: Q3 2026 - Filings
- 18 days ago - Isofol Medical AB Transcript: BioStock Life Science Summit 2026 - Transcripts
- 2 months ago - Isofol Medical AB Transcript: Investing in Life Science 2026 - Transcripts
- 2 months ago - Isofol Medical AB Quarterly report: Q2 2026 - Filings
- 6 months ago - Isofol Medical AB Quarterly report: Q1 2026 - Filings
- 8 months ago - Isofol Medical AB Slides: FY 2026 - Filings
- 8 months ago - Isofol Medical AB Slides: Corporate presentation - Filings
- 9 months ago - Isofol Medical AB Annual report: Q4 2025 - Filings